| |
The PrepQuant™ system automates nucleic acid extraction, concentration, and quantification processes into a single sample preparation run contributing to improving the accuracy, reproducibility, and quality of genomic research.
Hitachi High-Tech Corporation ("Hitachi High-Tech") has jointly developed the PrepQuant™ system ("the system"), an integrated nucleic acid extraction system with built-in quantification, with Invivoscribe, Inc. ("Invivoscribe", San Diego, California, U.S.A.), a global provider of blood cancer testing kits, bioinformatics software, and clinical services.
Since 2022, Hitachi High-Tech and Invivoscribe (invivoscribe.com) have been collaborating*1 to create new value in the field of molecular diagnostics. The initiative involves combining Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory expertise with Hitachi High-Tech's core capabilities in automation, measurement and analysis in order to carry out research and development aimed at providing solutions relating to cancer diagnosis and monitoring through the course of therapy.
The system has fully automated the processes of extraction, concentration and quantification of nucleic acid*2. Previously, each process required different equipment and methods. The system now enables a series of processes to be performed automatically through a single integrated platform, reducing costs, workload and processing time. The system can handle large-volume samples, including 2 mL of blood and 8 mL of plasma, and contributes to high-quality genomic analysis data for research applications, including studies related to cancer measurable residual disease*3 and liquid biopsy*4 testing.
Invivoscribe launched the system in the United States in April 2026 and will showcase the PrepQuant™ platform with cartridge extraction kits at the annual American Association for Cancer Research (AACR) meeting in San Diego, California, U.S.A., which will be held April 17 to 22, 2026.
Hitachi High-Tech is working to create healthcare innovations that support optimization of healthcare across the board, including molecular diagnostics and other high-quality, highly functional in-vitro diagnostic methods, as well as radiation therapy that reduce the patient’s burden, we aim to “create a society without fear of cancer.” Going forward, we will continue to share the expertise and knowledge that we have cultivated in the field of in-vitro diagnostics, with digital technologies to provide healthcare solutions that support offerings of personalized medical care for each and every patient, thereby contributing a harmonized society where environment, wellbeing, economic growth are in balance.
*1. News Release May 2022
*2. Nucleic acid: A generic term for DNA (deoxyribonucleic acid) and RNA (ribonucleic acid), which play an important role in storing genetic information and building proteins.
*3. Minimal residual disease: A highly sensitive detection and analysis of minimal residual cancer cells remaining in the body after cancer therapy.
*4. Liquid biopsy: An approach that analyzes tumor-derived biomolecules in liquid samples such as blood and plasma, and is used in cancer related research and genomic analysis.
*For Research Use Only. Not for use in diagnostic procedures.
About Hitachi, Ltd.’s Connective Industries Sector
At Hitachi High-Tech, which belongs to the Industrial Solutions Business Unit of Hitachi, Ltd.’s Connective Industries (CI) Sector, we provide industrial solutions that maximize lifetime value for customers and transform industries globally, contributing to a prosperous society. We achieve this through the combination of strong products and HMAX Industry, a next-generation suite of solutions that combine data from an extensive installed base of digitalized assets with domain knowledge and advanced AI.
About Hitachi High-Tech
Hitachi High-Tech (hitachi-hightech.com) provides cutting-edge technologies, products and services to society and customers with its corporate vision of "Changing the World and Future with the Power of Knowledge" to contribute to a sustainable global environment, healthy, safe and secure lives, and the sustained development of science and industry. We manufacture and sell clinical analyzers, biotechnology products and radiation therapy systems in the healthcare field, semiconductor manufacturing and inspection equipment in the semiconductor field, as well as analytical systems and electron microscopes used in environmental fields and materials research. We are also engaged in a wide range of business areas globally, providing high added-value solutions in battery, communication infrastructure, railway inspection, digital and other industrial and social infrastructure fields. We provide solutions through a deeper understanding of the issues facing society and our customers to contribute to realizing a sustainable society. The company's consolidated revenues for FY2024 were approx. JPY 756.5 billion.
|
Informatics.aj[.]hitachi-hightech.com 
